Global Mrna Therapeutics Market
Market Size in USD Billion
CAGR :
%

![]() |
2025 –2032 |
![]() |
USD 8.05 Billion |
![]() |
USD 36.25 Billion |
![]() |
|
![]() |
Global mRNA Therapeutics Market Segmentation, By Type (Therapeutic mRNA Vaccines, Therapeutic mRNA Proteins, and Others), Delivery System (Lipid Nanoparticles, Polymeric Nanoparticles, and Others), Application (Oncology, Infectious Diseases, Genetic Disorders, and Others), End User (Pharmaceutical Companies, Research Institutes, and Hospitals), Distribution Channel (Direct Sales and Retail Sales) – Industry Trends and Forecast to 2032
MRNA Therapeutics Market Analysis
The mRNA therapeutics market has undergone significant advancements in recent years, driven by breakthrough developments in vaccine technologies and personalized medicine. The rapid development of COVID-19 vaccines using mRNA technology has sparked increased interest in the potential of mRNA for treating a wide array of diseases. This technology allows for the direct delivery of genetic material into cells, enabling the body to produce therapeutic proteins, antibodies, or vaccines. Key innovations include the development of lipid nanoparticle (LNP) delivery systems, which protect mRNA molecules from degradation, ensuring efficient and targeted delivery to cells. As a result, mRNA -based treatments are becoming crucial in the fight against infectious diseases, cancer, and genetic disorders.
In addition, the integration of AI and machine learning to optimize mRNA design and delivery methods has the potential to revolutionize personalized medicine, providing tailored therapies based on genetic profiles. As research expands, there is growing potential for mRNA to be applied to a broad range of diseases, including rare genetic disorders and cancer immunotherapies. The increasing investments by pharmaceutical companies and the evolving regulatory landscape are driving the growth of the mRNA therapeutics market, with collaborations between biopharmaceutical companies and academic institutions further accelerating research and development.
MRNA Therapeutics Market Size
The global mRNA therapeutics market size was valued at USD 8.05 billion in 2024 and is projected to reach USD 36.25 billion by 2032, with a CAGR of 16.70% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
MRNA Therapeutics Market Trends
"Expansion Beyond Infectious Diseases"
The mRNA therapeutics market is rapidly expanding beyond its initial focus on infectious diseases, driven by the success of mRNA vaccines such as those developed for COVID-19. This breakthrough technology is now being leveraged to tackle a broader range of medical conditions, particularly in oncology and genetic disorders. Companies such as Moderna and BioNTech are pioneering mRNA-based cancer vaccines that can potentially target and treat cancers previously difficult to address. By instructing cells to produce specific proteins, mRNA technology enables precision therapies that target cancer cells more effectively while minimizing damage to healthy tissues. In addition, mRNA-based approaches are being explored for gene therapies aimed at treating rare genetic disorders, offering potential cures where traditional treatments fall short. Furthermore, advancements in vaccine platforms targeting diseases such as malaria, HIV, and others are accelerating, highlighting the versatile and transformative potential of mRNA in revolutionizing treatment paradigms across diverse therapeutic areas.
Report Scope and MRNA Therapeutics Market Segmentation
Attributes |
MRNA Therapeutics Key Market Insights |
Segments Covered |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Key Market Players |
Moderna, Inc. (U.S.), BioNTech SE (Germany), Pfizer Inc. (U.S.), CureVac AG (Germany), Translate Bio (U.S.), Arcturus Therapeutics (U.S.), Gennova Biopharmaceuticals Ltd (India), Sanofi (France), GlaxoSmithKline (GSK) (U.K.), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Eli Lilly and Co. (U.S.), Novartis International AG (Switzerland), Regeneron Pharmaceuticals (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), VaxArt, Inc. (U.S.), Medicago Inc. (Canada), Ribon Therapeutics (U.S.), and Genenta Science S.p.A. (Italy) |
Market Opportunities |
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
MRNA Therapeutics Market Definition
The mRNA therapeutics is the segment of the biotechnology and pharmaceutical industry focused on the development, production, and commercialization of treatments that utilize messenger RNA (mRNA) technology. These treatments involve introducing synthetic mRNA into the body to instruct cells to produce specific proteins that can treat, prevent, or mitigate the effects of various diseases.
MRNA Therapeutics Market Dynamics
Drivers
- COVID-19 Vaccine Success
The rapid development and global distribution of mRNA-based COVID-19 vaccines by companies such as Pfizer-BioNTech and Moderna has revolutionized vaccine development. The ability to design, test, and distribute vaccines in under a year demonstrated the power and flexibility of mRNA technology. This success has not only provided an effective response to the pandemic but has also established mRNA as a viable platform for future vaccine development. Its speed and adaptability make it an attractive option for responding to new infectious diseases, and its success has accelerated adoption in other therapeutic areas such as cancer and genetic disorders, further increasing the growth of the mRNA therapeutics market.
- Rising Cancer Prevalence
Cancer rates are increasing globally, creating a pressing need for new and more effective treatments. mRNA-based cancer vaccines represent a promising frontier in oncology. These vaccines can be engineered to stimulate the immune system to recognize and attack specific tumor cells, offering a potential solution for cancers that have been difficult to treat with traditional therapies. This approach aligns with the growing trend of precision medicine, where treatments are tailored to the individual’s genetic makeup, thus boosting the adoption of mRNA-based therapies in oncology. Companies such as Moderna and BioNTech are actively developing mRNA cancer vaccines, indicating the growing role of this technology in cancer treatment.
Opportunities
- Rising Investments in mRNA Research
Since the success of COVID-19 vaccines, investments in mRNA research have surged, with both public and private sectors eager to explore its broader applications. Governments and pharmaceutical companies are increasingly funding projects to advance mRNA-based treatments, not just for vaccines but also for gene therapies, cancer therapies, and rare genetic diseases. This investment climate is fueling innovation, with companies expanding their mRNA research pipelines and exploring new therapeutic indications. The growing interest in mRNA is fostering collaborations and partnerships, accelerating the development of novel therapies and expanding market opportunities.
- Technological Advancements
Advancements in mRNA delivery systems have significantly improved the effectiveness and applicability of mRNA-based therapeutics. Technologies such as lipid nanoparticles and polymeric carriers enhance the stability and delivery of mRNA molecules to target cells, making them more efficient and safer. These improvements have overcome some of the early challenges of mRNA therapy, such as degradation and limited tissue penetration. With better delivery mechanisms, mRNA therapies are becoming more viable for clinical use across a range of diseases, including cancer and genetic disorders, which in turn drives the growth of the market.
Restraints/Challenges
- Manufacturing and Scalability Issues
One of the key challenges facing the mRNA therapeutics market is the manufacturing and scalability of these therapies. mRNA production requires sophisticated techniques to ensure the integrity, purity, and consistency of the molecules, which can make large-scale production both challenging and costly. The complexity of the production process and the need for stringent quality control measures can lead to delays and higher prices, limiting the widespread availability of mRNA-based treatments. Addressing these scalability challenges is essential for ensuring that mRNA therapies can be produced in sufficient quantities to meet global demand, especially in the context of pandemics and large-scale public health initiatives.
- Regulatory and Safety Concerns
Despite the success of mRNA vaccines, the long-term safety and efficacy of mRNA-based therapeutics remain under scrutiny. Regulatory agencies such as the FDA and EMA are closely monitoring the development of mRNA therapies, with ongoing clinical trials necessary to gather long-term safety data. Concerns around potential side effects and the need for rigorous testing before widespread adoption are significant barriers. The approval process for new mRNA therapies will require extensive clinical trials to demonstrate not just efficacy but also long-term safety, which may delay the broader application of mRNA technology across various disease areas.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
MRNA Therapeutics Market Scope
The market is segmented on the basis of product, delivery system, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Therapeutic mRNA Vaccines
- Infectious Diseases (COVID-19, Influenza, HIV, Malaria, etc.)
- Cancer Vaccines
- Therapeutic mRNA Proteins
- Protein Replacement Therapies (e.g., for genetic disorders)
- Enzyme Replacement Therapies
- Others
- mRNA Gene Therapy
- mRNA-based Diagnostics
Delivery System
- Lipid Nanoparticles
- Cationic Lipid Nanoparticles
- Ionizable Lipid Nanoparticles
- Polymeric Nanoparticles
- Biodegradable Polymeric Nanoparticles
- Non-biodegradable Polymeric Nanoparticles
- Others
- Protein-based Carriers
- Liposomes
Application
- Oncology
- Solid Tumors
- Hematologic Malignancies (Blood Cancers)
- Infectious Diseases
- Viral Infections
- Bacterial Infections
- Parasitic Infections
- Genetic Disorders
- Rare Genetic Diseases
- Inherited Metabolic Disorders
- Others
- Cardiovascular Diseases
- Autoimmune Diseases
End User
- Research and Academic Institutes
- Hospitals
- Outpatient Facilities
- Others
Distribution Channel
- Direct Sales
- Retail Sales
MRNA Therapeutics Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, product, delivery system, application, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, and Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America is expected to dominate the mRNA therapeutics market due to significant investments in research and development and the presence of major pharmaceutical companies such as Moderna, Pfizer, and BioNTech. The United States, in particular, benefits from a robust healthcare infrastructure, strong demand for innovative therapeutics, and a supportive regulatory environment that accelerates the development and approval of mRNA-based treatments. These factors contribute to North America's dominance in the global market.
Asia-Pacific region, especially China, Japan, and India, is expected to witness rapid growth in the mRNA therapeutics market over the forecast period. This growth is fueled by increased government spending on healthcare, expanding biotechnology sectors, and rising investments in medical research. As these countries prioritize improving healthcare infrastructure and access to advanced therapies, the adoption of mRNA-based treatments is expected to rise significantly, positioning the region as a key growth driver in the global market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
MRNA Therapeutics Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
MRNA Therapeutics Market Leaders Operating in the Market Are:
- Moderna, Inc. (U.S.)
- BioNTech SE (Germany)
- Pfizer Inc. (U.S.)
- CureVac AG (Germany)
- Translate Bio (U.S.)
- Arcturus Therapeutics (U.S.)
- Gennova Biopharmaceuticals Ltd (India)
- Sanofi (France)
- GlaxoSmithKline (GSK) (U.K.)
- Johnson & Johnson (U.S.)
- Merck & Co., Inc. (U.S.)
- Eli Lilly and Co. (U.S.)
- Novartis International AG (Switzerland)
- Regeneron Pharmaceuticals (U.S.)
- AstraZeneca (U.K.)
- Bayer AG (Germany)
- VaxArt, Inc. (U.S.)
- Medicago Inc. (Canada)
- Ribon Therapeutics (U.S.)
- Genenta Science S.p.A. (Italy)
Latest Developments in MRNA Therapeutics Market
- In July 2024, GSK and CureVac announced a restructured collaboration, transforming it into a licensing agreement. GSK acquires full global rights to develop, manufacture, and commercialize mRNA vaccines for influenza and COVID-19, including combinations. CureVac receives €400 million upfront, with up to €1.05 billion in milestones and royalties. The agreement replaces previous financial terms and allows CureVac to retain rights to additional infectious disease targets. This partnership strengthens GSK’s mRNA capabilities for developing next-generation vaccines, leveraging CureVac’s technology and GSK’s expertise. Completion of the agreement is pending regulatory approvals
- In November 2023, BioNTech acquired AexeRNA, a company specializing in mRNA delivery technology, continuing its strategy of seeking bolt-on acquisitions. AexeRNA focuses on developing mRNA therapeutics using its proprietary Lipid Nanoparticle (LNP) delivery system, a technology developed at the University of Pennsylvania and George Mason University. BioNTech's acquisition aligns with its ongoing investment in novel mRNA delivery technologies
- In January 2023, two major mRNA developers, Moderna and BioNTech, made significant acquisitions. Moderna is acquiring OriCiro Genomics, a Japan-based company specializing in cell-free DNA synthesis and amplification technology, for $85 million. Meanwhile, BioNTech is purchasing the London-based company InstaDeep for $439 million, with the potential for up to $243 million in milestone payments. This acquisition will enable BioNTech to utilize InstaDeep's artificial intelligence and machine learning platforms to advance the discovery and development of immunotherapies and vaccines
- In September 2021, Sanofi completed its acquisition of Translate Bio, enhancing its mRNA capabilities for developing new vaccines and therapies. The acquisition strengthens Sanofi's mRNA Center of Excellence, focusing on immunology, oncology, and rare diseases
- In February 22, 2021, Arcturus Therapeutics acquired an exclusive license from Alexion Pharmaceuticals for patent-pending nucleic acid purification technologies. This acquisition allows Arcturus to scale up and accelerate mRNA production with higher purity, supporting its development of mRNA therapeutics for infectious diseases, liver, and respiratory rare diseases. Arcturus has been building proprietary expertise in RNA manufacturing since its founding in 2013 and now extends its intellectual property portfolio
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.